GYRE THERAPEUTICS, INC. (GYRE) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, GYRE THERAPEUTICS, INC.'s filing signal turned positive.

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates in the PRC through its subsidiary Gyre Pharmaceuticals, which has established a strong commercial presence with ETUARY(R) (pirfenidone) for pulmonary fibrosis, generating $106.1 million in sales in 2025. Gyre Pharmaceuticals also markets Etorel(R) (nintedanib) and Contiva(R) (avatrombopag) in the PRC. The company is advancing its pipeline, including lead candidate Hydronidone for liver fibrosis, with plans for U.S. regulatory submissions. Gyre Therapeutics is headquartered in San Diego, California, and employs 618 people across its operations.

Revenue is primarily driven by the sales of ETUARY(R) (pirfenidone) in the PRC for pulmonary fibrosis. The company also generates revenue from Etorel(R) (nintedanib) and Contiva(R) (avatrombopag), which were launched in 2025.